Protalix BioTherapeutics (PLX) Stock Price, News & Analysis

Company Overview

Protalix BioTherapeutics, Inc. is a biopharmaceutical company that develops recombinant therapeutic proteins using its proprietary ProCellEx plant-cell-based protein expression platform. The platform is designed to produce complex proteins in genetically engineered plant cells and supports the development of enzyme replacement therapies and other biologic medicines.

The company’s products include Elfabrio (pegunigalsidase alfa-iwxj), an enzyme replacement therapy for adults with Fabry disease, and Elelyso (taliglucerase alfa), an enzyme replacement therapy for Gaucher disease type 1. Protalix has commercialized these products through collaborations, including arrangements with Chiesi Farmaceutici for Elfabrio and Pfizer for Elelyso in certain markets. The company is also advancing additional product candidates for rare diseases and other conditions.

Founded in 1993, Protalix is based in Carmiel, Israel, and serves international markets through regulatory approvals and commercial partnerships. Its research, manufacturing and development activities are focused on applying plant-cell-based production technology to biologic medicines for patients with significant unmet medical needs.

Key Stats

• Today's Range: $2.73 to $2.82
• 50-Day Range: $2.22 to $2.84
• 52-Week Range: $1.60 to $3.19
• Volume: 302,265 shs
• Average Volume: 911,394 shs
• Market Capitalization: $221.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Buy

Protalix BioTherapeutics Stock Analysis - MarketRank™

Protalix BioTherapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 494th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Protalix BioTherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Protalix BioTherapeutics has a consensus price target of $12.00, representing about 336.4% upside from its current price of $2.75.

Amount of Analyst Coverage

Protalix BioTherapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 3,000.00%

Earnings Growth

Earnings for Protalix BioTherapeutics are expected to grow by 3,000.00% in the coming year, from $0.01 to $0.31 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Protalix BioTherapeutics is -21.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Protalix BioTherapeutics is -21.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Protalix BioTherapeutics has a P/B Ratio of 5.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for PLX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Protalix BioTherapeutics does not currently pay a dividend.

Dividend Growth

Protalix BioTherapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Protalix BioTherapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for PLX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added Protalix BioTherapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Protalix BioTherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.70% of the stock of Protalix BioTherapeutics is held by insiders.

Percentage Held by Institutions

16.53% of the stock of Protalix BioTherapeutics is held by institutions.

Company Calendar

• Last Earnings: 5/09/2025
• Today: 9/25/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSE:PLX
• CIK: 1006281
• Web: www.protalix.com
• Phone: 201-696-9345
• Fax: 972-4988-9489
• Employees: 226
• Year Founded: 1994

Price Target and Rating

• Average Price Target for Protalix BioTherapeutics: $12.00
• High Price Target: $12.00
• Low Price Target: $12.00
• Potential Upside/Downside: +336.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.23
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 275.00
• P/E Growth: N/A
• Net Income: $8.31 million
• Net Margins: -21.03%
• Pretax Margin: -21.00%
• Return on Equity: -30.89%
• Return on Assets: -11.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.98
• Quick Ratio: 1.27

Sales & Book Value

• Annual Sales: $80.62 million
• Price / Sales: 2.75
• Cash Flow: $0.15 per share
• Price / Cash Flow: 17.80
• Book Value: $0.47 per share
• Price / Book: 5.85

Miscellaneous

• Outstanding Shares: 80,572,000
• Free Float: 68,995,000
• Market Cap: $221.57 million
• Optionable: Optionable
• Beta: 0.02